Eone Diagnomics Genome Center Balance Sheet Health
Financial Health criteria checks 2/6
Eone Diagnomics Genome Center has a total shareholder equity of ₩72.4B and total debt of ₩55.6B, which brings its debt-to-equity ratio to 76.8%. Its total assets and total liabilities are ₩164.1B and ₩91.7B respectively.
Key information
76.8%
Debt to equity ratio
₩55.59b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩10.23b |
| Equity | ₩72.38b |
| Total liabilities | ₩91.72b |
| Total assets | ₩164.09b |
Recent financial health updates
Is Eone Diagnomics Genome Center (KOSDAQ:245620) Weighed On By Its Debt Load?
Apr 06
Eone Diagnomics Genome Center (KOSDAQ:245620) Is Carrying A Fair Bit Of Debt
Dec 16Recent updates
There's No Escaping Eone Diagnomics Genome Center Co., Ltd.'s (KOSDAQ:245620) Muted Revenues Despite A 43% Share Price Rise
Feb 29Is Eone Diagnomics Genome Center (KOSDAQ:245620) Weighed On By Its Debt Load?
Apr 06If You Had Bought Eone Diagnomics Genome Center (KOSDAQ:245620) Shares A Year Ago You'd Have Earned 54% Returns
Feb 24Do Insiders Own Lots Of Shares In Eone Diagnomics Genome Center Co., Ltd. (KOSDAQ:245620)?
Jan 20Eone Diagnomics Genome Center (KOSDAQ:245620) Is Carrying A Fair Bit Of Debt
Dec 16Financial Position Analysis
Short Term Liabilities: A245620's short term assets (₩38.3B) do not cover its short term liabilities (₩45.0B).
Long Term Liabilities: A245620's short term assets (₩38.3B) do not cover its long term liabilities (₩46.7B).
Debt to Equity History and Analysis
Debt Level: A245620's net debt to equity ratio (62.7%) is considered high.
Reducing Debt: A245620's debt to equity ratio has increased from 10.8% to 76.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A245620 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A245620 is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.